Cancer as an evolutionary and ecological processAids-related malignanciesHow ageing processes influence cancerEpigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction?Two genetic hits (more or less) to cancerIAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancerCell cycle, CDKs and cancer: a changing paradigmThe role of FLT3 in haematopoietic malignanciesThe role of peroxisome proliferator-activated receptors in carcinogenesis and chemopreventionBarrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesisCovalent histone modifications--miswritten, misinterpreted and mis-erased in human cancersModes of resistance to anti-angiogenic therapyRetroviral oncogenes: a historical primerA decade of exploring the cancer epigenome - biological and translational implicationsMucins in cancer: function, prognosis and therapyReplication licensing and cancer--a fatal entanglement?Adoptive cell transfer: a clinical path to effective cancer immunotherapyThe first 30 years of p53: growing ever more complexA census of human cancer genesDeregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancerTargeting DNA topoisomerase II in cancer chemotherapyEmerging mechanisms of resistance to androgen receptor inhibitors in prostate cancerPrecision medicine for cancer with next-generation functional diagnosticsRethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancerSympathetic nervous system regulation of the tumour microenvironmentCancer imaging by optical coherence tomography: preclinical progress and clinical potential.Serine, glycine and one-carbon units: cancer metabolism in full circleMitochondrial ROS in cancer: initiators, amplifiers or an Achilles' heel?RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesisA RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressorHijacked in cancer: the KMT2 (MLL) family of methyltransferasesHeterogeneity of epidermal growth factor receptor signalling networks in glioblastomaMicroRNA biogenesis pathways in cancerHIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progressionTargeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyondFAK in cancer: mechanistic findings and clinical applicationsMechanisms of disseminated cancer cell dormancy: an awakening fieldRas superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics.Epithelial-mesenchymal transitions in tumour progression
P1433
Q22122026-A83B6E83-9CA2-4C6E-BF54-8A8E98C1548AQ22251046-32A3E600-6BB2-468F-8471-697790E2B60CQ22251048-E1F434FB-3E2D-4A24-9A20-4BE29FC56714Q22251049-AA6E08CC-5955-4E2A-AF10-B051E943DB53Q22251289-6445734B-B184-481B-A5C6-1698479B5F00Q24292870-B3F77D2D-FA7C-4EBD-890D-F40D9BD18C3AQ24314465-777FB4A6-8C27-4A2A-B07B-3191D1A97519Q24319174-3A3FD7BF-55A6-4C3A-9A42-B423CB41900BQ24601222-DC0C90F6-8A4E-4727-95DC-03759F316176Q24602426-3D447A3C-79D7-47BC-B229-541CD5A3F8F0Q24605342-4AE7D86E-633B-43A2-AC46-71B54C7D794BQ24608005-E3F74B9D-3485-4381-A579-11A4A96472BFQ24611142-DE09C871-0273-4E31-AB9F-424413BC985FQ24614467-23D35BFD-9736-43F0-BC96-BDF73A14925EQ24633765-68867DBE-A19F-4191-90F6-79350AC7291FQ24644766-4996D74E-EE1A-4D7A-BDB6-EE8DC18FFF6AQ24644774-90712C83-83E8-43A6-B7ED-7A06E1137414Q24645732-C34408B6-632A-4D1F-93DC-B03D27F8C56DQ24647081-791D2455-EA5C-4AD1-8C44-0857A6FEED8DQ24648025-19EF1094-DEC9-45E9-821C-71CBEC8664FBQ24649711-F23F000F-32DD-4FEB-9099-09EA41135F93Q26777310-8B6F264F-17B1-44CB-B24C-77A437B43E17Q26780232-4A81F1C6-92B2-43B3-A393-06BF93AB2DADQ26780387-11D17EE4-9970-44FD-95C8-8DCF20457107Q26795614-B7C70BCF-BD1D-4DD3-BA9B-34E6C0581061Q26823084-5A07F3AC-3991-40F2-978E-BBD4878B3469Q26828610-3F3D0BB8-4395-4FC2-9884-366BC73B3141Q26852282-8A5832FD-DA45-4A8E-9CB8-1B2D4AA94BFCQ26853207-502D1854-C931-46A0-9007-173CA16B0EB0Q27003534-45BF9216-9F8C-4346-99D8-74A32F447FBBQ27006839-E7AA27A4-6A72-4D7B-B9D1-659EAFC6C4BFQ27013006-B75FF4BE-D2FD-41D8-B667-49B359B413C4Q27013841-A4BC6FE4-E86A-44BC-9492-733A40E0F381Q27025886-525AA592-1366-4FEF-8BD2-EB3BF171AF7DQ27026323-59715D1E-7B84-4244-B5AD-79A11E0AF2AFQ27026533-13AC99EA-433D-49F6-B3A7-00BD17A11FD8Q27027015-706AD0F2-9A19-4784-9E43-5CB0D323701AQ27690752-4C6CF25D-C85E-4237-AAC0-353B39193204Q27851412-4A34D6FB-0E52-4B7B-8F7E-810CFAE76E3AQ27860487-DFCBFFD7-A8BA-49F5-A854-1BC08A2C14C9
P1433
description
begutachtete wissenschaftliche Zeitschrift
@de
peer-reviewed scientific journal
@en
revista científica
@es
revue scientifique
@fr
rivista scientifica
@it
vědecký časopis
@cs
wetenschappelijk tijdschrift van Nature Publishing Group
@nl
рецензований науковий журнал
@uk
वैज्ञानिक पत्रिका
@hi
英语期刊
@zh
name
Nature Reviews Cancer
@ast
Nature Reviews Cancer
@da
Nature Reviews Cancer
@de
Nature Reviews Cancer
@en
Nature Reviews Cancer
@es
Nature Reviews Cancer
@fi
Nature Reviews Cancer
@fr
Nature Reviews Cancer
@id
Nature Reviews Cancer
@it
Nature Reviews Cancer
@kk
type
label
Nature Reviews Cancer
@ast
Nature Reviews Cancer
@da
Nature Reviews Cancer
@de
Nature Reviews Cancer
@en
Nature Reviews Cancer
@es
Nature Reviews Cancer
@fi
Nature Reviews Cancer
@fr
Nature Reviews Cancer
@id
Nature Reviews Cancer
@it
Nature Reviews Cancer
@kk
altLabel
Nat Rev Cancer
@de
Nat Rev Cancer
@ru
Nat. Rev. Cancer
@de
Nat. Rev. Cancer
@ru
Nature Rev Cancer
@de
Nature Reviews. Cancer
@en
prefLabel
Nature Reviews Cancer
@ast
Nature Reviews Cancer
@da
Nature Reviews Cancer
@de
Nature Reviews Cancer
@en
Nature Reviews Cancer
@es
Nature Reviews Cancer
@fi
Nature Reviews Cancer
@fr
Nature Reviews Cancer
@id
Nature Reviews Cancer
@it
Nature Reviews Cancer
@kk
P3181
P4616
P646
P1055
P1058
P1156
P1250
P1277
P1476
Nature Reviews Cancer
@en
P2002
NatureRevCancer
P236
P407
P571
2001-01-01T00:00:00Z